-+ 0.00%
-+ 0.00%
-+ 0.00%
Telomir Selects Linical for Phase 1/2 Trial of Telomir-Zn in Triple-Negative Breast Cancer
Share
Listen to the news
Telomir Selects Linical for Phase 1/2 Trial of Telomir-Zn in Triple-Negative Breast Cancer
  • Telomir Pharmaceuticals selected Linical to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer.
  • Clinical initiation is targeted for the first quarter of 2027, supported by executed clinical trial agreements.
  • The study will evaluate the oral therapy alone for safety, tolerability and preliminary antitumor activity.
  • Preclinical research has already demonstrated antitumor activity in triple-negative breast cancer models, supporting further clinical investigation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880011) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending